Injection pantop 40

Reading File

Finding Sources

Searching the Web

pantoprazole 40mg injection IV uses dose mechanism clinical pharmacology

Finding Sources

Reading File

Here is a complete clinical summary of Injection Pantop 40 (Pantoprazole Sodium 40 mg IV):

Injection Pantop 40 - Pantoprazole Sodium 40 mg (IV)

Drug Class

Proton Pump Inhibitor (PPI) - substituted benzimidazole

Mechanism of Action

Pantoprazole is a prodrug. After IV administration, it distributes to gastric parietal cells and accumulates in their acidic secretory canaliculi. There it is activated (converted to a cyclic sulphenamide) and irreversibly and covalently binds to the H⁺/K⁺-ATPase enzyme (the proton pump) at the secretory surface. This blocks the final step of gastric acid secretion - both basal and stimulated - regardless of the stimulus (histamine, gastrin, acetylcholine).

The effect persists longer than 24 hours even though the plasma half-life is only ~1 hour, because the enzyme inhibition is irreversible.

Katzung's Basic & Clinical Pharmacology, 16th Ed.

Formulation

Lyophilized (freeze-dried) powder in a glass vial
Each vial: pantoprazole sodium equivalent to 40 mg pantoprazole + edetate disodium (1 mg) + NaOH (pH adjuster)
Reconstituted solution pH: 9.0 - 10.5

Pharmacokinetics

Parameter	Value
Half-life (t½)	~1 hour
Cmax (40 mg IV over 15 min)	5.52 ± 1.42 mcg/mL
AUC	5.4 ± 1.5 mcg·hr/mL
Volume of distribution	11-23.6 L (mainly extracellular fluid)
Total clearance	7.6-14 L/h
Protein binding	~98% (mainly albumin)
Metabolism	Hepatic, primarily CYP2C19; minor CYP3A4
Excretion	~71% urine, ~18% feces (via bile)

Pharmacokinetics are linear (dose-proportional from 10-80 mg IV)
No accumulation with multiple daily doses

Indications for IV Use

Parenteral route is used when the oral/NG route is not feasible:

Erosive esophagitis / GERD - when patient cannot take oral medications
Peptic ulcer bleeding - after endoscopic hemostasis: 80 mg loading dose, then 8 mg/hr continuous infusion for 72 hours
Zollinger-Ellison Syndrome (pathological hypersecretion) - 80 mg/day or 160 mg/day in divided doses for rapid control
Prophylaxis of stress-related mucosal bleeding in critically ill ICU patients
H. pylori eradication - as part of triple/quadruple therapy (when oral not possible)

Dosing

Indication	Dose	Route/Rate
GERD / Erosive esophagitis	40 mg once daily	Slow IV bolus over 2-5 min, OR IV infusion over 15 min
PU bleeding (after endoscopy)	80 mg loading, then 8 mg/hr x 72 hr	IV infusion
Zollinger-Ellison	80 mg/day (up to 160 mg in divided doses)	IV infusion
Stress ulcer prophylaxis	40 mg once daily	IV infusion in 100 mL NS

Diluent: Normal saline (0.9% NaCl) or 5% Dextrose.

Adverse Effects

Common (1-5%): Diarrhea, headache, abdominal pain (only slightly more than placebo)

With long-term use:

Nutritional: Reduced absorption of Vitamin B12, non-heme iron, calcium, and magnesium
Bone: Modest increase in risk of hip fracture (reduced calcium absorption / possible effect on osteoclasts)
Renal: Associated with acute interstitial nephritis and chronic kidney disease in observational studies
Infectious: Increased risk of C. difficile infection (acid suppression allows colonization); community-acquired pneumonia
Hypomagnesemia with prolonged use (can be severe)
Elevated gastrin (hypergastrinemia): Reflex hypergastrinemia due to acid suppression; associated with ECL cell hyperplasia with very long-term use

IV-specific: Thrombophlebitis at injection site

Drug Interactions

Clopidogrel: PPIs (especially omeprazole) may reduce antiplatelet effect via CYP2C19 competition; pantoprazole has the least interaction among PPIs
Ketoconazole / Itraconazole: Reduced absorption of azole antifungals (need acidic pH)
Methotrexate: PPIs may reduce methotrexate clearance - monitor
Calcineurin inhibitors / certain antiretrovirals: Altered absorption
Warfarin: Monitor INR with prolonged PPI use

Contraindications / Precautions

Hypersensitivity to pantoprazole or any substituted benzimidazole
Liver impairment: Dose reduction considered (pantoprazole is hepatically metabolized); max 40 mg/day in severe hepatic impairment
Renal impairment: No dose adjustment needed
Pregnancy: Category B - safety not fully established; use only if clearly needed
Stop at least 14 days before serum Chromogranin A (CgA) measurement (PPI use falsely elevates CgA, which is a marker for neuroendocrine tumors)

Administration Tips

Reconstitute with 10 mL NS → give as slow bolus over ≥ 3 minutes (or dilute in 100 mL for 15-min infusion)
Do NOT mix with other drugs in the same line (highly alkaline pH 9-10.5)
Use within 12 hours after reconstitution
Check for discoloration or particulates before use

Sources: Katzung's Basic & Clinical Pharmacology 16th Ed. | Sabiston Textbook of Surgery | FDA Prescribing Information (Protonix IV) | NHS Cornwall Pantoprazole Guideline

This is a shared conversation. Sign in to Orris to start your own chat.